Several analysts have recently updated their ratings and price targets for Intercept Pharmaceuticals (NASDAQ: ICPT):

  • 10/4/2017 – Intercept Pharmaceuticals was downgraded by analysts at JMP Securities from an “outperform” rating to a “market perform” rating.
  • 10/4/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 9/26/2017 – Intercept Pharmaceuticals had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
  • 9/26/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $201.00 price target on the stock.
  • 9/26/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at JMP Securities. They now have a $140.00 price target on the stock, down previously from $150.00.
  • 9/26/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $135.00 price target on the stock, down previously from $275.00.
  • 9/26/2017 – Intercept Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $200.00 to $244.00. They now have an “outperform” rating on the stock.
  • 9/23/2017 – Intercept Pharmaceuticals had its price target lowered by analysts at Leerink Swann from $120.00 to $66.00. They now have a “market perform” rating on the stock.
  • 9/23/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $332.00 price target on the stock.
  • 9/22/2017 – Intercept Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/22/2017 – Intercept Pharmaceuticals had its price target lowered by analysts at Laidlaw from $118.00 to $90.00. They now have a “hold” rating on the stock.
  • 9/22/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $112.00 price target on the stock, down previously from $232.00.
  • 9/22/2017 – Intercept Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $50.00 price target on the stock, down previously from $75.00.
  • 9/22/2017 – Intercept Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/22/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $160.00 price target on the stock, down previously from $221.00.
  • 9/22/2017 – Intercept Pharmaceuticals was downgraded by analysts at UBS AG from an “outperform” rating to a “market perform” rating.
  • 9/22/2017 – Intercept Pharmaceuticals was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $92.00 price target on the stock, down previously from $150.00.
  • 9/21/2017 – Intercept Pharmaceuticals was downgraded by analysts at Wells Fargo & Company from an “outperform” rating to a “market perform” rating. They now have a $95.00 price target on the stock, down previously from $265.00. They wrote, “an increased risk of serious liver injury and death.” The letter resulted in a 25 percent selloff in Intercept’s stock on Thursday, and some Wall Street analyst’s felt it prudent to take action.Wells Fargo’s Jim Birchenough downgraded Intercept’s stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA’s letter contains new pieces of information that weren’t included in the prior “Dear Healthcare Provider Letter,” the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva’s launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths.”We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE’s),”
  • 9/20/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $275.00 price target on the stock.
  • 9/19/2017 – Intercept Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Citigroup Inc.. They now have a $150.00 price target on the stock.
  • 9/15/2017 – Intercept Pharmaceuticals had its “ourperform” rating reaffirmed by analysts at Wedbush. They now have a $253.00 price target on the stock.
  • 9/14/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $232.00 price target on the stock.
  • 9/14/2017 – Intercept Pharmaceuticals is now covered by analysts at Royal Bank Of Canada. They set an “outperform” rating and a $244.00 price target on the stock.
  • 9/14/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $200.00 price target on the stock.
  • 9/13/2017 – Intercept Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $69.00 price target on the stock.
  • 9/13/2017 – Intercept Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $275.00 price target on the stock.
  • 9/13/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $332.00 price target on the stock.
  • 9/13/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 9/13/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $221.00 price target on the stock.
  • 9/1/2017 – Intercept Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/25/2017 – Intercept Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $253.00 price target on the stock.
  • 8/24/2017 – Intercept Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/8/2017 – Intercept Pharmaceuticals had its “underweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $69.00 price target on the stock, up previously from $60.00. They wrote, “In AESOP, OCA-treated PSC patients demonstrated significant decrease from baseline in alkaline phosphatase (ALP) of -22% compared with placebo-treated patients’ increase of +1% at 24 weeks,” the firm said.”Additionally, CONTROL demonstrated atorvastatin’s ability to reduce elevations of LDL-C in OCA-treated patients by 40-48mg/dL.”

Shares of Intercept Pharmaceuticals, Inc. (ICPT) opened at 68.73 on Thursday. The stock’s market capitalization is $1.73 billion. The firm’s 50-day moving average is $94.11 and its 200-day moving average is $111.08. Intercept Pharmaceuticals, Inc. has a one year low of $54.98 and a one year high of $156.65.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, beating the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. The business had revenue of $30.89 million during the quarter, compared to analysts’ expectations of $27.50 million. During the same period in the previous year, the business posted ($3.14) EPS. The business’s quarterly revenue was up 459.6% compared to the same quarter last year. On average, analysts expect that Intercept Pharmaceuticals, Inc. will post ($13.99) earnings per share for the current fiscal year.

In other Intercept Pharmaceuticals news, CEO Mark Pruzanski sold 1,532 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $58.87, for a total transaction of $90,188.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $126.76, for a total transaction of $27,506.92. Following the sale, the director now owns 3,710 shares of the company’s stock, valued at $470,279.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,920 shares of company stock valued at $672,822. Company insiders own 9.20% of the company’s stock.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.